



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Charles T. Esmion and Jun Xu

Serial No: 09/139,425

Art Unit: 1643

Filed: August 25, 1998

Examiner: W. Sandals

For: TARGETING OF MOLECULES TO LARGE VESSEL  
ENDOTHELIUM USING PCR

RECEIVED

JUL 27 2001

TECH CENTER 1600/2900

#16

Assistant Commissioner  
for Patents  
Washington, D. C. 20231POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST  
AND REVOCATION OF PRIOR POWERS

Sir:

As owner of the entire interest of the above-identified patent application, all powers of attorney previously given are hereby revoked and the following attorneys and agents are hereby appointed to prosecute and transact all business in the Patent and Trademark Office connected therewith:

Patrea L. Pabst  
Zhaoyang Li  
Rivka MonheitRegistration No. 31,294  
Registration No. 46,872  
Registration No. P-45,731

Please send all correspondence relating to the above-identified patent application to:

Patrea L. Pabst  
HOLLAND & KNIGHT LLP  
One Atlantic Center  
1201 West Peachtree Street, Suite 2000  
Atlanta, Georgia 30309-3400(404) 817-8473 - Telephone  
(404) 817-8588 - Telefax

U.S.S.N. 06/139,425  
Filed August 25, 1998  
Power of Attorney by Assignee of Entire  
Interest and Reversion of Prior Powers

The undersigned signatory (whose title is supplied below) is empowered to act on behalf of the assignee identified below, and has reviewed all the documents in the chain of title of the patent application and, to the best of undersigned's knowledge and belief, title is in the assignee.

OKLAHOMA MEDICAL RESEARCH FOUNDATION

By:

Name:

Title:


Larry S. Kennedy  
Larry S. Kennedy  
Director Technology Transfer

Date:

July 16, 2001

ATL: #452099 v1

OMRF 171



Under the Patent and Trademark Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

### STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Charles T. Esmon and Jun Xu  
Application No./Patent No.: 09/139,425 Filed/Issue Date: August 23, 1998  
Entitled: TARGETING OF MOLECULES TO LARGE VESSEL ENDOTHELIUM USING PCR  
Oklahoma Medical Research Foundation, a Corporation  
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of an undivided part interest

In the patent application/patent identified above by virtue of either:

A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel 9792, Frame 0379, or for which a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
2. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

(NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the PTO. See MPEP 302-302.6)

The undersigned (whose title is supplied below) is empowered to sign this statement on behalf of the assignee.

July 16, 2001  
Date

[Signature]  
Signature  
Charles T. Kennedy  
Typed or printed name  
Director Technology Transfer  
Title

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

TECH CENTER 1600/2900

JUL 27 2001

RECEIVED